82.46
1.07 (1.31%)
| Previous Close | 81.39 |
| Open | 81.48 |
| Volume | 260,746 |
| Avg. Volume (3M) | 583,923 |
| Market Cap | 4,883,208,192 |
| Price / Earnings (TTM) | 41.86 |
| Price / Earnings (Forward) | 20.96 |
| Price / Sales | 3.48 |
| Price / Book | 3.28 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | 8.81% |
| Operating Margin (TTM) | 11.83% |
| Diluted EPS (TTM) | 2.04 |
| Quarterly Revenue Growth (YOY) | 9.80% |
| Quarterly Earnings Growth (YOY) | 6.80% |
| Total Debt/Equity (MRQ) | 57.24% |
| Current Ratio (MRQ) | 4.87 |
| Operating Cash Flow (TTM) | 225.16 M |
| Levered Free Cash Flow (TTM) | 172.75 M |
| Return on Assets (TTM) | 4.32% |
| Return on Equity (TTM) | 9.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bullish | Mixed |
| Medical Instruments & Supplies (Global) | Bullish | Mixed | |
| Stock | Merit Medical Systems, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 3.13 |
|
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Growth |
| % Held by Insiders | 2.23% |
| % Held by Institutions | 109.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 109.00 (Piper Sandler, 32.19%) | Buy |
| Median | 107.00 (29.76%) | |
| Low | 104.00 (Canaccord Genuity, 26.12%) | Buy |
| Average | 106.75 (29.46%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 85.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barrington Research | 31 Oct 2025 | 106.00 (28.55%) | Buy | 87.54 |
| 07 Oct 2025 | 103.00 (24.91%) | Buy | 82.70 | |
| Needham | 31 Oct 2025 | 108.00 (30.97%) | Buy | 87.54 |
| Piper Sandler | 31 Oct 2025 | 109.00 (32.19%) | Buy | 87.54 |
| Canaccord Genuity | 16 Oct 2025 | 104.00 (26.12%) | Buy | 80.81 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |